Keywords
mieloma múltiple
inhibidor selectivo de la exportación nuclear (ISEN)
exportina-1 (XPO-1)
How to Cite
Abstract
Despite improvements in treatment, multiple myeloma (MM) remains an incurable disease. Selinexor is a first-in-class, oral, selective inhibitor of exportin-1 (XPO1), with a different mechanism of action than currently available drugs. The US Food and Drug Administration (FDA) approved it in combination with dexamethasone or with bortezomib and dexamethasone for patients with relapsed/refractory MM (RRMM). There are several ongoing clinical trials in combination with different treatment regimens with promising results. The main toxicities of selinexor are hematological (mainly thrombocytopenia) and gastrointestinal disorders (nausea and diarrhea), however they are manageable with adequate support measures. Selinexor is a novel drug, an alternative for patients "triple-class refractory" who do not have other therapeutic options.
References
2. Kumar SK, Dimopoulos MA, Kastritis E y col. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31: 2443–2448.
3. Gandhi UH, Cornell RF, Lakshman A y col. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33: 2266–2275.
4. Giuliani N, Accardi F, Marchica V y col. Novel targets for the treatment of relapsing multiple myeloma. Expert Rev Hematol. 2019;12: 481–496.
5. Richter J, Madduri D, Richard S y col. Selinexor in relapsed/refractory multiple myeloma. Ther Adv Hematol. 2020;11: 2040620720930629.
6. Barbara Muz, Feda Azab, Pilar de la Puente y col. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Transl Oncol. 2017;10: 632–640.
7. Chari A, Vogl DT, Gavriatopoulou M y col. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019;381: 727–738.
8. Grosicki S, Simonova M, Spicka I y col. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396: 1563–1573.
9. Turner JG, Kashyap T, Dawson JL y col. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7: 78896–78909.
10. Selinexor and Backbone Treatments of Multiple Myeloma Patients - ClinicalTrials.gov. [cited 1 Apr 2021]. Available: https://clinicaltrials.gov/ct2/show/NCT02343042
11. Jakubowiak AJ, Jasielec JK, Rosenbaum CA y col. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019;186: 549–560.
12. Moreau P, Mateos MV, Berenson JR y col. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. The Lancet Oncology. 2018. pp. 953–964.
13. Gasparetto C, Schiller GJ, Callander NS y col. A Phase 1b/2 Study of selinexor, carfilzomib, and dexamethasone (SKd) in relapsed/refractory multiple myeloma (RRMM). ASH; 2019. Available: https://ashpublications.org/blood/article-abstract/134/Supplement_1/3157/423953
14. White D, LeBlanc R, Venner C y col. Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma and Leukemia. 2019. p. e55.
15. Chen CI, Bahlis NJ, Gasparetto C y col. Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM). Blood. 2020. pp. 18–19.
16. Li C, Cao W, Que Y y col. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11: e346.
17. Mikhael J, Noonan KR, Faiman B y col. Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clin Lymphoma Myeloma Leuk. 2020;20: 351–357.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar